BIO Plans Lobbying Push To Improve Payments For Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
The Biotechnology Industry Organization is adding its lobbying muscle to diagnostic industry efforts to improve payment policies for molecular tests, hoping for a warm reception from lawmakers who are already focused on personalized medicine issues.